Patents Assigned to Neurovance, Inc.
  • Crystalline compounds
    Patent number: 9856217
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: January 2, 2018
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • Methods of treating fragile X associated disorders, ADHD, and autism spectrum disorder
    Patent number: 9839627
    Abstract: Provided are novel methods comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to a patient in need thereof.
    Type: Grant
    Filed: December 9, 2014
    Date of Patent: December 12, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony McKinney, Frank Gentile, Timothy Hsu, Franklin Bymaster, Walter Piskorski, Richard Welter
  • 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
    Patent number: 9737506
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Grant
    Filed: November 1, 2015
    Date of Patent: August 22, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Phil Skolnick, Anthony Basile, Zhengming Chen, Joseph W. Epstein
  • Crystalline compounds
    Patent number: 9708261
    Abstract: The present invention relates to crystalline forms of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane hydrochloride and compositions comprising the same and methods of making and using the same.
    Type: Grant
    Filed: June 17, 2016
    Date of Patent: July 18, 2017
    Assignee: NEUROVANCE, INC.
    Inventors: Anthony Alexander McKinney, Franklin Bymaster, Walter Piskorski, Fred J. Fleitz, Yonglai Yang, David A. Engers, Valeriya Smolenskaya, Venkat Kusukuntla
  • NOVEL METHODS
    Publication number: 20160303076
    Abstract: Provided are novel methods comprising administering a therapeutically effective amount of (1R,5S)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form, to a patient in need thereof.
    Type: Application
    Filed: December 9, 2014
    Publication date: October 20, 2016
    Applicant: Neurovance, Inc.
    Inventors: Anthony MCKINNEY, Frank GENTILE, Timothy HSU, Franklin BYMASTER, Walter PISKORSKI, Richard WELTER
  • 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
    Patent number: 9205074
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: December 8, 2015
    Assignee: Neurovance, Inc.
    Inventors: Phil Skolnick, Anthony Basile, Zhengming Chen, Joseph W. Epstein
  • 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, methods for their preparation and their use as medicaments
    Patent number: 9133159
    Abstract: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
    Type: Grant
    Filed: April 3, 2013
    Date of Patent: September 15, 2015
    Assignee: NEUROVANCE, INC.
    Inventors: Phil Skolnick, Zhengming Chen
  • 1-aryl-3-azabicyclo[3.1.0]hexanes: preparation and use to treat neuropsychiatric disorders
    Patent number: 8877798
    Abstract: The invention provides novel, multiply-substituted 1-aryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including depression and anxiety.
    Type: Grant
    Filed: May 5, 2013
    Date of Patent: November 4, 2014
    Assignee: Neurovance, Inc.
    Inventors: Phil Skolnick, Anthony Basile, Zhengming Chen, Joseph W. Epstein
  • Novel 1-Heteroaryl-3-Azabicyclo[3.1.0]Hexanes Methods For Their Preparation And Their Use As Medicaments
    Publication number: 20140303207
    Abstract: The invention provides novel 1-heteroaryl-3-azabicyclo[3.1.0]hexanes, and related processes and intermediates for preparing these compounds, as well as compositions and methods employing these compounds for the treatment and/or prevention of central nervous system (CNS) disorders, including but not limited to depression and anxiety.
    Type: Application
    Filed: April 3, 2013
    Publication date: October 9, 2014
    Applicant: NEUROVANCE, Inc.
    Inventors: Phil SKOLNICK, Zhengming Chen
  • Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
    Publication number: 20140206740
    Abstract: The present invention relates to (1R,5S)-(+)-1-(naphthalen-2-yl)-3-azabicyclo[3.1.0]hexane and pharmaceutical compositions thereof, and methods employing their use in the treatment of conditions affected by monoamine neurotransmitters, including ADHD and substance abuse.
    Type: Application
    Filed: June 2, 2013
    Publication date: July 24, 2014
    Applicant: Neurovance, Inc.
    Inventors: Anthony Alexander McKINNEY, Frank Bymaster